Key terms

About INMB

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest INMB news

May 02 11:10am ET Biotech Alert: Searches spiking for these stocks today by TipRanks May 01 4:08pm ET INmune Bio files $250M mixed securities shelf by TipRanks Apr 30 1:45pm ET Inmune Bio’s Promising INKmune Therapy and Strong Financials Merit a Buy Rating by TipRanks Apr 30 8:26am ET INmune Bio provides update on two patients from Phase 1b AD trial by TipRanks Apr 30 5:35am ET INKmune Program’s Promise in mCRPC Treatment: A High-Risk, High-Reward Investment with a Favorable Safety Profile by TipRanks Apr 29 8:11am ET INmune completes first cohort, initiates second of Phase 1/2 study of INKmune by TipRanks Apr 25 12:55pm ET Inmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financials by TipRanks Apr 25 9:09am ET INmune Bio to sell 986,000 shares at $9.84 in registered direct offering by TipRanks Apr 23 8:06am ET INmune Bio announces 24-month stability validation of XPro by TipRanks Apr 22 8:12am ET INmune Bio raises $4.8M in gross proceeds through registered direct offering by TipRanks Apr 12 1:35am ET Inmune Bio’s INB03 Shows Promise as Pan-Immune Checkpoint Inhibitor: A Buy Rating from Analyst Joel Beatty by TipRanks Apr 08 8:19am ET INmune Bio presents data on INB03’s role as immune check point by TipRanks Apr 02 4:10pm ET Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB) by TipRanks Mar 06 1:56pm ET Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments by TipRanks Mar 05 8:11am ET INmune Bio reports ‘significant’ EEG improvement in patients treated with Xpro by TipRanks

No recent press releases are available for INMB

INMB Financials

1-year income & revenue

Key terms

INMB Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

INMB Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Warren Buffett (L), CEO of Berkshire Hathaway, and Vice Chairman Charlie Munger attend the 2019 annual shareholders meeting in Omaha, Nebraska, May 3, 2019.
Johannes Eisele/AFP/Getty Images
Warren Buffett holds first Berkshire Hathaway meeting without Charlie Munger
People walk by the New York Stock Exchange (NYSE) on March 20, 2024 in New York City. The Dow was up slightly in late morning trading as traders analyze the Federal Reserve's latest decision on interest rates.
Spencer Platt/Getty Images
Stocks close higher after softer-than-expected jobs report fuels hopes of an earlier rate cut
People work at a Starbucks in Manhattan on February 02, 2024 in New York City.
Spencer Platt/Getty Images
Restaurants are competing for frugal diners’ dollars
Traders work on the floor of the New York Stock Exchange during afternoon trading on April 09, 2024 in New York City.
Michael M. Santiago/Getty Images/File
Sell in May and go away? Think again